MedTrace Logo

Ticagrelor for PCI Post Thrombolysis

NCT01930591 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2016-11-22

No results posted yet for this study

Summary

Ticagrelor is a first line therapy along with aspirin for patients undergoing primary PCI for STEMI. However, many patients are still treated with fibrinolytic therapy and the safety and efficacy of Ticagrelor has not been investigated in this patients population. The present study is proposed to study the safety and efficacy of Ticagrelor in patients undergoing PCI post fibrinolytic therapy for STEMI.

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

Ticagrelor

180 mg bolus followed by 90 mg BID

DRUG

Clopidogrel

300 mg bolus followed by 75 mg OD

Sponsors & Collaborators

  • Prairie Vascular Research Inc.

    collaborator INDUSTRY

  • Unity Health Toronto

    lead OTHER

Principal Investigators

  • Payam Dehghani, MD · Prairie Vascular Research Network, Regina, Saskatchewan

  • Asim Cheema, MD · St. Michael's Hospital, Toronto, Ontario

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-10-31
Completion
2016-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01930591 on ClinicalTrials.gov